No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TELA TELA Bio
- 5.720
- +0.010+0.18%
Close Jun 5 16:00 ET
141.03MMarket Cap-3487P/E (TTM)
5.795High5.440Low159.88KVolume5.760Open5.710Pre Close900.34KTurnover1.02%Turnover RatioLossP/E (Static)24.66MShares11.26052wk High9.81P/B90.11MFloat Cap4.23552wk Low--Dividend TTM15.75MShs Float23.545Historical High--Div YieldTTM6.22%Amplitude4.235Historical Low5.631Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | TELA Bio Appoints Jeffrey Blizard to Its Board of Directors
Analysts Are Bullish on Top Healthcare Stocks: TELA Bio (TELA), Rezolute (RZLT)
Analysts Offer Insights on Healthcare Companies: Evogene (EVGN), TELA Bio (TELA) and InfuSystem Holdings, Inc. (INFU)
Express News | TELA Bio Appoints Greg Firestone as Chief Commercial Officer
TELA Bio, Inc. (NASDAQ:TELA) Q1 2024 Earnings Call Transcript
TELA Bio First Quarter 2024 Earnings: US$0.23 Loss per Share (Vs US$0.63 Loss in 1Q 2023)
Comments
$TELA Bio(TELA.US$
NEWS
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
TELA Bio, Inc. announces the U.S. commercial launch of OviTex IHR, a reinforced tissue matrix for inguinal hernia repair. The product offers trocar-compatibility for laparoscopic and robotic procedures, with three configurations available. OviTex has a strong clinical track record with low recurrence rates and high pati...
NEWS
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
TELA Bio, Inc. announces the U.S. commercial launch of OviTex IHR, a reinforced tissue matrix for inguinal hernia repair. The product offers trocar-compatibility for laparoscopic and robotic procedures, with three configurations available. OviTex has a strong clinical track record with low recurrence rates and high pati...
$TELA Bio(TELA.US$
Beat revenue estimates and near miss on GAAP.
FDA approved surgical device
Buy this asap
Beat revenue estimates and near miss on GAAP.
FDA approved surgical device
Buy this asap
Despite TELA Bio's high revenue growth, its P/S ratio barely aligns with industry median, indicating public skepticism about future growth. Its current stock price could be attractive, yet it shows two risk signs.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg